UK-based EUSA Pharma says it can now concentrate solely on developing its two oncology assets while hunting for new ones after agreeing to sell its critical care portfolio to Belgium-based Laboratories SERB (SERB) for an undisclosed sum.
Lee Morley, EUSA Pharma’s chief executive officer, told Scrip the deal "now lets us focus on our oncology assets without...








